During his presentation at the 44th Annual J.P. Morgan Healthcare Conference, CEO Doug Ingram highlighted that Sarepta’s four approved Duchenne muscular dystrophy therapies — Exondys 51, Vyondys 53, Amondys 45 and Elevidys — collectively treat fewer than 10% of the estimated 30,000 patients in the U.S. with DMD. He noted that improved diagnostic rates and expanded genotype screening programs could double eligible patient identification by 2028. Ingram emphasized ongoing label expansion efforts for younger ambulatory boys and discussed real‐world evidence studies showing a 40% slower rate of functional decline in treated patients over 24 months compared to natural history controls.

Sarepta’s siRNA platform now encompasses five wholly owned discovery programs targeting rare neuromuscular and central nervous system disorders, including a lead candidate for Pompe disease entering IND‐enabling studies in mid-2026. Preclinical data presented show more than 90% knockdown of mutant transcripts in key tissues after a single dose in animal models. Ingram forecasted initiation of two Phase I trials by year-end for a spinocerebellar ataxia candidate and a refractory epilepsy program, projecting a combined peak sales potential of over $1.5 billion in underserved patient populations.

Sarepta reported preliminary and unaudited fourth quarter 2025 net product revenues of $450 million, a 25% increase over Q4 2024, and full-year 2025 revenues of $1.7 billion, up 22% year-over-year. Cash, cash equivalents and investments stood at $1.3 billion as of December 31, 2025, providing runway through 2028 even as the company advances six clinical programs. Management reiterated guidance for 2026 R&D spending of $600–650 million, supporting both late-stage DMD trials and early-stage siRNA pipeline activities.